Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Clarity Pharmaceuticals Ltd. ( (AU:CU6) ) is now available.
Clarity Pharmaceuticals announced that data from its Phase II Co-PSMA investigator-initiated trial of 64Cu-SAR-bisPSMA in men with recurrent prostate cancer have been accepted for an oral presentation at the European Association of Urology Congress 2026, underscoring the scientific importance and visibility of its lead diagnostic agent. The trial demonstrated that 64Cu-SAR-bisPSMA PET/CT detected significantly more, smaller, and earlier lesions than standard-of-care 68Ga-PSMA-11 in patients with low PSA levels, adding to a growing body of clinical and real-world evidence that the product outperforms existing PSMA PET agents and reinforcing Clarity’s positioning as it advances two registrational Phase III trials and targets a share of the expanding multi-billion-dollar PSMA imaging market.
The most recent analyst rating on (AU:CU6) stock is a Buy with a A$5.00 price target. To see the full list of analyst forecasts on Clarity Pharmaceuticals Ltd. stock, see the AU:CU6 Stock Forecast page.
More about Clarity Pharmaceuticals Ltd.
Clarity Pharmaceuticals Ltd. is an ASX-listed clinical-stage radiopharmaceutical company focused on developing next-generation targeted copper theranostic products for oncology. Its lead candidate, 64Cu-SAR-bisPSMA, is designed to improve prostate cancer imaging and therapy by leveraging proprietary SAR chelator technology that tightly binds copper isotopes, offering both diagnostic (Cu-64) and therapeutic (Cu-67) applications in the growing PSMA PET imaging market.
Average Trading Volume: 2,645,688
Technical Sentiment Signal: Sell
Current Market Cap: A$1.24B
For detailed information about CU6 stock, go to TipRanks’ Stock Analysis page.